Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a pivotal role in both physiological and pathological processes. While essential for embryonic development, wound healing, and the menstrual cycle, dysregulated angiogenesis contributes significantly to disease progression, particularly in cancer. Tumor cells rely on a continuous supply of oxygen and nutrients to grow and metastasize, which they obtain through tumor angiogenesis. This process is driven by an imbalance between pro-angiogenic and anti-angiogenic factors, leading to what is known as the “angiogenic switch.” Although vascular endothelial growth factor (VEGF) inhibitors have been the cornerstone of anti-angiogenic therapy, their clinical utility is limited by issues such as toxicity, resistance, and modest improvements in progression-free survival. As a result, there has been growing interest in alternative targets, with angiopoietins emerging as promising candidates.
Angiopoietins are ligands of the Tie-2 receptor tyrosine kinase and play crucial roles in vascular maturation, stabilization, and remodeling. Among them, Angiopoietin-1 (Ang-1) acts as a stabilizing agonist, promoting vessel integrity, while Angiopoietin-2 (Ang-2) functions as a context-dependent antagonist that destabilizes vessels under pathological conditions like cancer. In tumors, Ang-2 is overexpressed and promotes vascular instability, facilitating sprouting angiogenesis and enabling tumor progression. Inhibiting Ang-2 can thus disrupt this pro-angiogenic environment, making it an attractive target for therapeutic intervention.
Several agents targeting angiopoietins have entered clinical development. Trebananib (AMG 386), a peptibody that inhibits both Ang-1 and Ang-2, has shown encouraging results in ovarian cancer. In a phase III trial, trebananib combined with paclitaxel significantly prolonged progression-free survival compared to placebo, demonstrating its potential in recurrent ovarian cancer. However, results in other settings such as breast and colorectal cancers have been mixed, indicating context-specific efficacy.CD85G Antibody supplier Similarly, CVX-060, a monoclonal antibody specifically targeting Ang-2, showed promise in renal and colorectal cancer models in preclinical studies, though clinical development was halted due to thromboembolic events.CD223 Antibody manufacturer
Newer agents include AMG 780, a dual inhibitor of Ang-1 and Ang-2, which demonstrated manageable safety and pharmacokinetics in early-phase trials. REGN 910 (Nesvacumab), a fully human anti-Ang-2 monoclonal antibody, has also shown acceptable safety profiles in patients with solid tumors. MEDI 3617, another selective Ang-2 inhibitor, has been evaluated in combination with chemotherapy and bevacizumab, although clinical activity remains limited.
Dual inhibitors represent a more advanced approach. Vanucizumab, which simultaneously targets VEGF-A and Ang-2, was tested in colorectal cancer but failed to outperform bevacizumab in terms of efficacy and safety. RG7716 (Faricimab), a bispecific antibody targeting both VEGF-A and Ang-2, has shown superior outcomes in ophthalmologic indications, particularly in diabetic macular edema and age-related macular degeneration, where dual inhibition proved more effective than monotherapy.PMID:34002235
In conclusion, angiopoietin inhibitors offer a compelling alternative or complementary strategy to existing anti-angiogenic therapies. Their ability to modulate vascular stability and counteract resistance mechanisms makes them valuable candidates for future combination regimens. Despite variable clinical outcomes across different cancers, ongoing research continues to refine patient selection and optimize dosing strategies. The success of dual-targeting agents in non-oncological diseases suggests that similar approaches may eventually yield breakthroughs in oncology, paving the way for more durable and effective anti-angiogenic treatments.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com